Ortho Clinical Diagnostics
Ortho Clinical Diagnostics, a leading player in the in vitro diagnostics industry, is headquartered in the United States. Founded in 1939, the company has established itself as a pioneer in blood testing and transfusion diagnostics, serving healthcare providers across the globe. With a strong presence in North America, Europe, and Asia, Ortho Clinical Diagnostics focuses on delivering innovative solutions that enhance laboratory efficiency and patient care. The company’s core offerings include advanced blood screening, clinical chemistry, and immunoassay systems, distinguished by their accuracy and reliability. Notable achievements include the development of the first FDA-approved blood screening test for HIV. With a commitment to quality and innovation, Ortho Clinical Diagnostics continues to solidify its market position as a trusted partner in the healthcare sector, driving advancements in diagnostic technology.
DitchCarbon Score
How does Ortho Clinical Diagnostics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ortho Clinical Diagnostics's score of 20 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Ortho Clinical Diagnostics's reported carbon emissions
In 2022, Ortho Clinical Diagnostics reported total emissions of approximately 26,371,000 kg CO2e for Scope 1 and 28,869,000 kg CO2e for Scope 2, reflecting their commitment to reducing carbon emissions. In 2021, the company recorded about 17,320,000 kg CO2e in Scope 1 and 27,971,000 kg CO2e in Scope 2, leading to a combined total of approximately 45,291,000 kg CO2e. This indicates a slight increase in emissions from 2021 to 2022. In 2020, Ortho's emissions were approximately 19,409,000 kg CO2e for Scope 1 and 26,398,000 kg CO2e for Scope 2, totalling around 45,807,000 kg CO2e. The company has shown a trend of managing its emissions effectively, with a notable decrease in Scope 1 emissions from 2020 to 2021. Despite the absence of specific reduction targets or climate pledges, Ortho Clinical Diagnostics continues to focus on sustainability and reducing its carbon footprint. The company’s GHG intensity has improved, with a reported value of 0.0222 metric tons CO2e per million USD in revenue for 2021, down from 0.0259 metric tons CO2e per million USD in 2020. This reflects their ongoing efforts to enhance operational efficiency and sustainability practices within the diagnostics industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2020 | 2021 | 2022 | |
|---|---|---|---|
| Scope 1 | 19,409,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 26,398,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ortho Clinical Diagnostics is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
